Trials / Unknown
UnknownNCT04524052
To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19
Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of Niclosamide (DWRX2003) following escalating doses of DWRX2003 administered as an intramuscular injection in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWRX2003 | Intramuscularly injection at pre-defined injection sites |
| DRUG | Placebo | Intramuscularly injection at pre-defined injection sites |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2020-08-24
- Last updated
- 2020-08-24
Source: ClinicalTrials.gov record NCT04524052. Inclusion in this directory is not an endorsement.